Show simple item record

dc.contributor.authorNyakas, Marta Sølvi
dc.contributor.authorAamdal, Elin
dc.contributor.authorJacobsen, Kari Dolven
dc.contributor.authorGuren, Tormod Kyrre
dc.contributor.authorAamdal, Steinar
dc.contributor.authorHagene, Kirsten Thorin
dc.contributor.authorBrunsvig, Paal Fr.
dc.contributor.authorYndestad, Arne
dc.contributor.authorHalvorsen, Bente
dc.contributor.authorTasken, Kristin Austlid
dc.contributor.authorAukrust, Pål
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorUeland, Thor
dc.date.accessioned2019-08-23T10:50:54Z
dc.date.available2019-08-23T10:50:54Z
dc.date.issued2019-03-01
dc.description.abstractNew therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients with metastatic or unresectable malignant melanoma, receiving treatment with ipilimumab in a national Phase IV study (NCT0268196). Expression of a panel of 17 inflammatory‐related markers reflecting different pathways including extracellular matrix remodeling and fibrosis, vascular inflammation and monocyte/macrophage activation were measured at baseline and the second and/or third course of treatment with ipilimumab. Six candidate proteins [endostatin, osteoprotegerin (OPG), C‐reactive protein (CRP), pulmonary and activation‐regulated chemokine (PARC), growth differentiation factor 15 (GDF15) and galectin‐3 binding‐protein (Gal3BP)] were persistently higher in non‐survivors. In particular, high Gal3BP and endostatin levels were also independently associated with poor 2‐year survival after adjusting for lactate dehydrogenase, M‐stage and number of organs affected. A 1 standard deviation increase in endostatin gave 1·74 times [95% confidence interval (CI) = 1·10–2·78, P = 0·019] and for Gal3BP 1·52 times (95% CI = 1·01–2·29, <i>P</i> = 0·047) higher risk of death in the adjusted model. Endostatin and Gal3BP may represent prognostic biomarkers for patients on ipilimumab treatment in metastatic melanoma and should be further evaluated. Owing to the non‐placebo design, we could only relate our findings to prognosis during ipilimumab treatment.en_US
dc.description.sponsorshipDepartment of Health, Oslo, Norway The Cancer Clinic, Oslo University Hospitalen_US
dc.descriptionSource at <a href=https://doi.org/10.1111/cei.13283>https://doi.org/10.1111/cei.13283. </a>en_US
dc.identifier.citationNyakas, M., Aamdal, E., Jacobsen, K.D., Guren, T.K., Aamdal, S., Hagene, K.T. ... Ueland, T. (2019). Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. <i>Clinical and Experimental Immunology, 197</i>(1), 74-82. https://doi.org/10.1111/cei.13283.en_US
dc.identifier.cristinIDFRIDAID 1717528
dc.identifier.doi10.1111/cei.13283
dc.identifier.issn0009-9104
dc.identifier.issn1365-2249
dc.identifier.urihttps://hdl.handle.net/10037/15999
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalClinical and Experimental Immunology
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.subjectanti-CTLA-4en_US
dc.subjectendostatinen_US
dc.subjectGal3BPen_US
dc.subjectimmunotherapyen_US
dc.subjectmelanomaen_US
dc.titlePrognostic biomarkers for immunotherapy with ipilimumab in metastatic melanomaen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record